Elkind-Hirsch KE, Chappell N, Seidemann E, et al. - This study sought to explore effectiveness of once-weekly exenatide and dapagliflozin (DAPA) alone and co-administered (EQW/DAPA), DAPA/extended release metformin (DAPA/MET), and phentermine topiramate extended release (PHEN/TPM) on metabolic parameters, body composition, and sex hormones in obese women with PCOS. Researchers randomized non-diabetic women (n=119; 18-45y) with BMI> 30 < 45 and PCOS (NIH criteria) in a single-blind fashion to EQW (2 mg weekly); DAPA (10 mg daily), EQW/DAPA (2 mg weekly/10 mg daily), DAPA (10 mg)/MET (2000mg XR daily) or PHEN (7.5 mg)/TPM (46mg ER daily) treatment for 24 weeks. It has been reported that dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.